The prevalence of acinetobacter baumannii (AB) as a cause of hospital infections has been
rising. Unfortunately, emerging colistin resistance limits therapeutic options and affects the …

Background: Nosocomial infection caused by Acinetobacter baumannii has emerged as a
serious problem world-wide. Finding the suitable drug is an important priority. The aim of this …

Aims: Colistin became the primary treatment option for Acinetobacters that had developed a
high rate of resistance to carbapenems which were the first-line therapy in the past, and now …

A potent synergy of a glycopeptide-colistin combination against Acinetobacter baumannii
has recently been described. We set out to assess the efficacy and safety of this combination …

Objective Nosocomial infection caused by carbapenem-resistant Acinetobacter baumannii is
a worldwide problem and treatment options remain controversial. This study investigated the …

Objectives To investigate the potential synergism of colistin in combination with N-
acetylcysteine against Acinetobacter baumannii strains grown in planktonic phase or as …

The alarming rise in antibiotic resistance has led to an increase in patient mortality and
health care costs. This problem is compounded by the absence of new antibiotics close to …

Introduction Acinetobacter baumannii antimicrobial resistance is a public health concern in
developing and developed countries, especially in the hospital setting. Understanding the …

Colistin heteroresistance (HR) refers to a bacterial population comprised of several
subpopulations with different levels of resistance to colistin. In this study, we discuss the …

This study aimed to address the relationship between the timing of colistin therapy and the
outcome, defined as all-cause mortality in the intensive care unit (ICU). A retrospective study …